Therapeutic potential of histamine H3 receptor antagonists in dementias

Drug News and Perspectives

Volumn 23, Issue 2, 2010, Pages 99-103

  Chazot, Paul L ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 [4 [3 (4 CYCLOPROPANECARBONYLPHENOXY)PROPYL] 1 PIPERAZINYL] 1 PROPANONE; 4 AMINOBUTYRIC ACID; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; A 317920; A 349821; ACETYLCHOLINE; BF 2649; CIPRALISANT; CIPROFIXAN; CIPROXIFAN; CLOBENPROPIT; DONEPEZIL; DOPAMINE; GSK 239512; GT 2331; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; JNJ 10181457; MEPYRAMINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN; PF 03654746; PLACEBO; THIOPERAMIDE; TIPROLISANT; UNCLASSIFIED DRUG; ZOLANTIDINE;

ALZHEIMER DISEASE; AMNESIA; ATTENTION DEFICIT DISORDER; AUTORADIOGRAPHY; BRAIN REGION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DEMENTIA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; LEARNING; MEMORY; MEMORY CONSOLIDATION; MEMORY DISORDER; NARCOLEPSY; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; RECEPTOR OCCUPANCY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ALZHEIMER DISEASE; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITION; DEMENTIA; DISEASE MODELS, ANIMAL; HISTAMINE H3 ANTAGONISTS; HUMANS; RECEPTORS, HISTAMINE H3; SCHIZOPHRENIA;

EID: 77952351891     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.2.1475899     Document Type: Review

References (38)

1. Arrang, J.M., Garbarg, M., Schwartz, J.C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302(5911): 832-837
2. Arrang, J.M., Schwartz, J.C., Schunack, W. Stereoselectivity of the histamine H3-presynaptic autoreceptor. Eur J Pharmacol 1985, 117(1): 109-114 (Pubitemid 16204506)
3. Lovenberg, T.W., Roland, B.L., Wilson, S.J. et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999, 55(6): 1101-1107
4. Tiligada, E., Zampeli, E., Sander, K., Stark, H. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 2009, 18(10): 1519-1531
5. Giannoni, P., Medhurst, A.D., Passani, M.B., Giovannini, M.G., Ballini, C., Corte, L.D., Blandina, P. Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3- benzazepin-7-yl)oxy]-N-methyl-3-pyridine carboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther 2010, 332(1): 164-172
6. Ciannoni, P., Passani, M.B., Nosi, D. et al. Heterogeneity of histaminergic neurons in the tuberomammillary nucleus of the rat. Eur J Neurosci 2009, 29(12): 2363-2374
7. Le, S., Gruner, J.A., Mathiasen, J.R., Marino, M.J., Schaffhauser, H. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 2008, 325(3): 902-909 (Pubitemid 351724342)
8. Fox, G.B., Esbenshade, T.A., Pan, J.B. et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl) benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 2005, 313(1): 176-190
9. Ligneau, X., Perrin, D., Landais, L. et al. BF2.649 [1-{3-[3-(4- Chlorophenyl)propoxy]-propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther 2007,320(1): 365-75.
10. Welty, N., Shoblock, J.R. The effects of thioperamide on extracellular levels of glutamate and CABA in the rat prefrontal cortex. Psychopharmacology (Berl) 2009, 207(3): 433-438
11. Hajos, M., Siok, C.J., Hoffmann, W.E., Li, S., Kocsis, B. Modulation of hippocampal theta oscillation by histamine H3 receptors. J Pharmacol Exp Ther 2008, 324(1): 391-398 (Pubitemid 350294183)
12. Blandina, P., Giorgetti, M., Bartolini, L. et al. Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 1996, 119(8): 1656-1664 (Pubitemid 27019542)
13. Passani, M.B., Cangioli, I., Baldi, E., Bucherelli, C., Mannaioni, P.F., Blandina, P. Histamine H3 receptor-mediated impairment of contextual fear conditioning and in-vivo inhibition of cholinergic transmission in the rat basolateral amygdala. Eur J Neurosci 2001, 14(9): 1522-1532 (Pubitemid 35463719)
14. Passani, M.B., Blandina, P., Browman, K.E., Fox, G.B. Cognitive functions, attention-deficit hyperactivity disorders, and Alzheimer's disease. In: Vohora, D., editor. The Third Histamine Receptor: CRC Press 2009. p. 213-39.
15. Giovannini, M.G., Bartolini, L., Bacciottini, L., Greco, L., Blandina, P. Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia. Behav Brain Res 1999, 104(1-2): 147-155 (Pubitemid 29421643)
16. Connelly, W.M., Shenton, F.C., Lethbridge, N. et al. The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 2009, 157(1): 55-63.
17. Pascoli, V., Boer-Saccomani, C., Hermant, J.F. H3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval. Psychopharmacology (Berl) 2009, 202(1-3): 141-152
18. Komater, V.A., Buckley, M.J., Browman, K.E., Pan, J.B., Hancock, A.A., Decker, M.W., Fox, G.B. Effects of histamine H3 receptor antagonists in two models of spatial learning. Behav Brain Res 2005, 159(2): 295-300.
19. Medhurst, A.D., Atkins, A.R., Beresford, I.J. et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007, 321(3): 1032-1045
20. Fox, G.B., Pan, J.B., Esbenshade, T.A. et al. Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 2002, 131(1-2): 151-161
21. Cowart, M., Faghih, R., Curtis, M.P. et al. 4-(2-[2-(2(R)- methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-amino-ethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. J Med Chem 2005, 48(1): 38-55.
22. Fox, G.B., Pan, J.B., Radek, R.J. et al. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 2003, 305(3): 897-908.
23. Esbenshade, T.A., Fox, G.B., Krueger, K.M. et al. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol 2004, 68(5): 933-945
24. Calici, R., Boggs, J.D., Aluisio, L., Fraser, I.C., Bonaventure, P., Lord, B., Lovenberg, T.W. JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 2009, 56(8): 1131-1137
25. Bertoni, S., Ballabeni, V., Flammini, L. et al. In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. Naunyn Schmiedebergs Arch Pharmacol 2008, 378(3): 335-343
26. Petroianu, G., Arafat, K., Sasse, B.C., Stark, H. Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie 2006, 61(3): 179-182
27. Medhurst, A.D., Roberts, J.C., Lee, J., Chen, C.P., Brown, S.H., Roman, S., Lai, M.K. Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid overexpressing TASTPM mice. Br J Pharmacol 2009, 157(1): 130-138
28. Jin, C.Y., Anichtchik, O., Panula, P. Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases. Br J Pharmacol 2009, 157(1): 118-129
29. Foley, A.G., Prendergast, A., Barry, C., Scully, D., Upton, N., Medhurst, A.D., Regan, C.M. H3 receptor antagonism enhances NCAM PSA-mediated plasticity and improves memory consolidation in odor discrimination and delayed match-to-position paradigms. Neuropsychopharmacology 2009, 34(12): 2585-2600
30. Miller, T.R., Milicic, I., Bauch, J. et al. Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br J Pharmacol 2009, 157(1): 139-149
31. An imaging study to investigate the distribution of GSK239512 in the brain (NCT00474513). ClinicalTrials.gov Web site, March 11, 2010.
32. Bridging study with GSK239512 in patients with mild to moderate Alzheimer's disease (NCT00675090). ClinicalTrials.gov Web site, March 11, 2010.
33. A phase I, healthy volunteer positron emission tomography study (NCT00730990). ClinicalTrials.gov Web site, March 11, 2010.
34. A study to evaluate the efficacy and safety of two doses of PF-03654746 in adults with attention deficit hyperactivity disorder (ADHD) (NCT00531752). ClinicalTrials.gov Web site, March 11, 2010.
35. Study to evaluate the efficacy and safety of GSK239512 in schizophrenia (NCT01009060). ClinicalTrials.gov Web site, March 11, 2010.
36. Study to demonstrate cognitive enhancing effects of BF2.649 (NCT00690274). ClinicalTrials.gov Web site, March 11, 2010.
37. Arnulf, I. Results of clinical trials of tiprolisant In narcolepsy and Parkinson's disease. 22nd ECNP Congress (Sept 12-16, Istanbul) 2009: S.19.05.
38. Efficacy and safety of BF2.649 in excessive daytime sleepiness (EDS) in Parkinson's disease (HARPS 1) (NCT01036139). ClinicalTrials.gov Web site, March 11, 2010.